Filing Flows › Puma Biotechnology (PBYI) › Q3 2026
Puma Biotechnology (PBYI) Q3 2026 earnings results (third quarter 2026)
8-K filed Nov 5, 2026
Puma Biotechnology (PBYI) reported revenue of $55.1M for the third quarter 2026 (Q3 2026), +1% from a year earlier and -2% from the quarter before. Operating margin was 9.6%, net earnings $6.0M (10.9% of revenue).
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $55.1M | -2% | +1% |
| Operating profit | $5.3M | -30% | -45% |
| Net earnings | $6.0M | -27% | -32% |
What changed
Revenue was $55.1M in Q3 2026, up 1% year over year and down 2% from the previous quarter. Product revenue, net was the largest line at 98% of revenue. Product revenue, net added $2.2M year over year (up 4%), 352% of the total change. Royalty revenue declined 62%.
Operating profit was $5.3M, a 9.6% margin (down 8.0 points year over year). Operating profit fell $4.3M even though revenue rose $625K versus Q3 2025, so costs grew faster than sales. Total costs grew 11% against revenue growth of 1%. The fastest-growing cost line was Cost of revenue (+25%). Net earnings were $6.0M, down 32% year over year. The effective tax rate was 3.2%.
Questions
What was Puma Biotechnology's revenue in the third quarter 2026?
Puma Biotechnology (PBYI) reported revenue of $55.1M for the third quarter 2026 (Q3 2026), +1% from a year earlier and -2% from the quarter before.
Was Puma Biotechnology profitable in the third quarter 2026?
Operating profit was $5.3M (9.6% of revenue) and net earnings $6.0M.
Source: Puma Biotechnology 8-K on SEC EDGAR.